Adiponectin vs PACAP-27
Head-to-head comparison of Adiponectin (Adiponectin (Acrp30, AdipoQ)) and PACAP-27 (Pituitary Adenylate Cyclase-Activating Polypeptide-27) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Adiponectin | PACAP-27 |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Adiponectin (Acrp30, AdipoQ) | Pituitary Adenylate Cyclase-Activating Polypeptide-27 |
| Molecular Weight | ~26.4 kDa (monomer) | 3158 Da |
| Half-Life | ~2-4 h | minutes |
| Amino Acids | 244 | 27 |
| Typical Dose | No approved human dose; research use only | Research-only: 0.1-1 nmol/kg |
| Route | IV|SC | Intraperitoneal/Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 86 | 220 |
| Research Status | Pre-clinical | Pre-clinical |
Adiponectin Benefits
- ✓insulin sensitivity
- ✓fatty-acid oxidation
- ✓AMPK activation
PACAP-27 Benefits
- ✓anti-apoptotic signaling
- ✓insulin secretagogue effect
- ✓reduced ER stress
- ✓islet cytoprotection
Adiponectin Dosing
not established|not established
PACAP-27 Dosing
0.1-1 nmol/kg in animal studies|10-100 nM in vitro|research-only intermittent dosing
Adiponectin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
PACAP-27 Side Effects
- ⚠flushing
- ⚠hypotension at high exposure
- ⚠headache
Research Overview
Adiponectin
Preclinical and translational studies link adiponectin signaling with better glycemic control, lower inflammation, and improved lipid handling. Recombinant adiponectin and receptor-targeting approaches remain research tools rather than approved diabetes therapies.
PACAP-27
PACAP-27 has been repeatedly shown to support beta-cell survival through cAMP/PKA and related pathways. In experimental models it mitigates cytokine damage, preserves insulin content, and helps maintain islet viability.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.